{"id":23572,"date":"2023-06-01T15:29:35","date_gmt":"2023-06-01T13:29:35","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=23572"},"modified":"2023-06-01T15:34:35","modified_gmt":"2023-06-01T13:34:35","slug":"inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/","title":{"rendered":"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals"},"content":{"rendered":"<p><strong>Inotrem<\/strong>, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients. Both studies reveal that the TREM-1 pathway plays a central role in major life-threatening immune dysregulations caused by severe infections, whether it is septic shock or severe forms of COVID-19. The findings presented further validate Inotrem\u2019s innovative approach to treat inflammatory diseases by targeting TREM-1.<\/p>\n<p>The two studies suggest that nangibotide, which targets TREM-1, is pathogen agnostic and has the potential to treat those very severe inflammatory conditions caused by both viral and bacterial infections. Both studies highlight the potential of nangibotide in the treatment of septic shock patients and of patients with severe forms of COVID-19 with a biomarker guided approach using soluble TREM-1 as predictive marker of response to targeted therapy.<\/p>\n<p>The first manuscript in The Lancet Respiratory Medicine is entitled \u201cProspective evaluation of the efficacy, safety, and the optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock: a double-blind, randomized, controlled, phase 2b trial\u201d and presents results from 355 septic shock patients. The primary outcome was the change in SOFA at day 5 compared to placebo in the pre-defined high soluble TREM-1 (\u2265 400 pg\/ml) group and in the overall population. Planned evaluation of the optimal sTREM-1 cut-off revealed increased clinically relevant benefits of high dose nangibotide at higher cutoffs (sTREM-1 \u2265 532 pg\/ml). The manuscript can be accessed via the following link: The Lancet Respiratory Medicine.<\/p>\n<p>The second manuscript in eClinicalMedicine, entitled \u201cEvaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID19 receiving respiratory support: results of the ESSENTIAL randomized, double-blind trial\u201d presents the Phase 2 results obtained in 220 COVID-19 patients receiving ventilatory support. In this study, nangibotide has a significant and positive impact on the clinical progression of the disease, as well as on the severity of the respiratory failure, secondary infection rates and notably mortality. The trial showed that sTREM-1 is an effective prognostic marker of outcome in severe COVID-19. The manuscript can be accessed via the following link: eClinicalMedicine.<\/p>\n<p>\u201cNangibotide is the first TREM-1 inhibitor and has the potential to become the first causal treatment of life-threatening immune dysregulations. This is an area with a major unmet medical need\u201d said <strong>Professor Bruno Fran\u00e7ois<\/strong>, Limoges University Hospital, and lead author on the two manuscripts.<\/p>\n<p>\u201cWe are excited to see this data published in The Lancet Respiratory Medicine and in eClinicalMedicine, two of the most established peer-reviewed medical journals in our field. These two publications come as a strong recognition of Inotrem\u2019s innovative scientific leadership regarding the role of the TREM-1 pathway and of our solid therapeutic approaches\u201d said <strong>Sven Zimmermann<\/strong>, CEO of Inotrem. \u201cWe look forward to bringing this potential new treatment option to patients suffering from severe and often fatal inflammatory conditions.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-23572","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-01T13:29:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-01T13:34:35+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals\",\"datePublished\":\"2023-06-01T13:29:35+00:00\",\"dateModified\":\"2023-06-01T13:34:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/\"},\"wordCount\":529,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/\",\"name\":\"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2023-06-01T13:29:35+00:00\",\"dateModified\":\"2023-06-01T13:34:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/","og_locale":"en_US","og_type":"article","og_title":"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals - ANDERA PARTNERS","og_description":"Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one...","og_url":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2023-06-01T13:29:35+00:00","article_modified_time":"2023-06-01T13:34:35+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals","datePublished":"2023-06-01T13:29:35+00:00","dateModified":"2023-06-01T13:34:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/"},"wordCount":529,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/","url":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/","name":"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2023-06-01T13:29:35+00:00","dateModified":"2023-06-01T13:34:35+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/inotrem-announces-publication-of-two-key-articles-on-nangibotide-phase-ii-programs-in-peer-reviewed-medical-journals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/23572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=23572"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/23572\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=23572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=23572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}